- Projects
Menu
On Wednesday, 30 November, President Mattarella and President Cassis have visited ETH Zurich, where they listened to the presentation of four researchers, including Dr. Michele Gregorini.
by Lara Pfuderer on ethz.ch
Michele completed his doctorate at ETH Zurich and he is now a Pioneer Fellow. Together with Dr. Bechtold and Prof. Stark, they co-founded the ETH spin-off Diaxxo, which develops DNA analysis systems that enable a precise, reliable, rapid and cost-effective diagnosis. Their point-of-care PCR tests deliver results within 30 minutes and allow doctors to detect and treat diseases accordingly quickly. Since the tests do not require a complex infrastructure and only cost around five francs, they are particularly suitable for resource-limited settings.
Original article: 
diaxxoPod (RUO)
Our in-vitro diagnostic test cartridge based on rapid Polymerase Chain Reaction (PCR) amplification technology. This cartridge can reliably detect and distinguish the mutants from UK (20I/501Y.V1, B.1.1.7 – VOC-202012/01) as well as the South African mutation (B.1.351 lineage).
The test cartridge is aimed to improve the public health situation by rapidly enabling the detection of variants of concern. The cartridge is designed for qualitative detection of variants of interest of the SARS-CoV-2 Viral RNA in saliva samples and it works in conjuction with diaxxoPCR.
The test cartridges are sold with all the necessary reagents pre-loaded in the reaction wells. The use of the test cartridges is therefore extremely simple:
diaxxoPod
The test cartridges are sold with all the necessary reagents pre-loaded in the reaction wells. The use of the test cartridges is therefore extremely simple:
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
